Brief: Orchestra Biomed Announces Rollout Of FDA-Approved Backbeat Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility
08/08/2025 12:36
Aug 8 (Reuters) - Orchestra Biomed Holdings Inc OBIO.O: ORCHESTRA BIOMED ANNOUNCES ROLLOUT OF FDA-APPROVED BACKBEAT GLOBAL PIVOTAL STUDY PROTOCOL UPDATE SIGNIFICANTLY EXPANDING PATIENT ELIGIBILITY Source text: ID:nGNX869vWp Further company coverage: OBIO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Orchestra Biomed Holdings
See all newsBrief: Orchestra Biomed Announces Pricing Of Public Offering
Orchestra BioMed slides after starting equity offering
Brief: Orchestra Biomed Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Orchestra Biomed Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
Orchestra BioMed Q2 revenue drops, net loss widens